このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発性成人膠芽腫 (GBM) に対する RNA 脂質粒子 (RNA-LP) ワクチン (ASPIRE)

2026年10月1日 更新者:University of Florida

再発性成人膠芽腫(GBM)に対するRNA脂質粒子(RNA-LP)ワクチンの第I相研究

This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

This is a first in human Phase I study of RNA-LP vaccines for recurrent adult glioblastoma. Participants will receive two study drug products. The first, pp65 RNA-LP, is a messenger RNA (mRNA) pp65 vaccine given for the first 3 vaccines to try to change how the tumor behaves. The second study drug RNA-LP, given as monthly vaccines 4-15, includes pp65 mRNA and tumor RNA from each patient's tumor tissue.

Patients will may receive up to three pp65 RNA-LP vaccines (DP1) before receiving full dose monthly RNA-LPs (RNA loaded lipid particles, RNA-LPs, DP2). All participants will receive the same number of vaccines, up to 15.

The immunotherapy with RNA lipid particle (RNA-LP) vaccines is the treatment portion of this study. During this study, we will make, test and give the RNA-LP vaccine therapy. As part of this study, participants will undergo up to 4 additional MRIs.

研究の種類

介入

入学 (推定)

24

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Florida
      • Gainesville、Florida、アメリカ、32608
        • UF Health

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~80年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age >/= 18years

  • Histopathologically proven GBM using the 2021 WHO Classification of Tumors of the CNS (WHO CNS5).

  • Unequivocal evidence of tumor progression as documented by brain MRI scan per RANO criteria.

  • Tumor must have a primary supratentorial component at the time of disease progression.

  • Patients must have received surgery and completed Fractionated Radiation therapy as frontline treatment for primary disease, either alone or with concurrent therapy (including temozolomide or another systemic chemotherapy agent). Patients must be at least 12 weeks post chemoradiation completion.

  • Patient must be at least 90 days from completion of prior radiation

  • Any adverse events patient has experienced from prior therapy must have resolved to ≤ Gr. 1 according to CTCAE (NCI Common Terminology Criteria for Adverse Events) v5.0 prior to enrollment

  • Patient must be either weaned off steroids or weaned onto physiologic dosing at the time of enrollment.

  • Patient must be a candidate for surgery/biopsy as acceptable standard of care for sterile collection of tumor material in a manner suitable for RNA extraction, amplification, and loading of lipid particles (LPs).

  • A diagnostic contrast-enhanced MRI of the brain must be performed preoperatively and postoperatively. Pre-op MRI must be performed within 28 days prior to study enrollment.

  • Performance Score: (KPS) ≥ 60. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

  • Bone Marrow:

    • ANC (Absolute neutrophil count) ≥ 1,500µl (unsupported)
    • Platelets ≥ 100/µl (unsupported for at least 3 days)
    • Hemoglobin > 8 g/dL
  • Renal:

    • BUN ≤ 25 mg/dl
    • Creatinine ≤ 1.7 mg/dl
  • Hepatic

    • Bilirubin ≤ 2.0 mg/dl
    • ALT ≤ 5 times institutional upper limits of normal for age
    • AST ≤ 5 times institutional upper limits of normal for age
  • Patient must be able to give consent.

  • For women of childbearing potential (WOCBP), negative serum/urine pregnancy test at enrollment.

  • WOCBP must be willing to use acceptable contraceptive methods to avoid pregnancy throughout the study and for at least 24 weeks after the last dose of study drug.

  • Males with female partners of childbearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 24 weeks following the last dose of study drug.

Exclusion Criteria:

  • Patients who received prior treatment with bevacizumab.

  • Known active infection (requiring treatment by antiviral or antibiotics) or immunosuppressive disease.

  • Patients with multifocal recurrent disease characterized by more than one enhancing lesion separated by noncontiguous T2/FLAIR signal abnormality. Patients with recurrence outside of the original tumor site are eligible if there is stability at the original site of disease.

  • Patients with uncontrolled seizure disorders

  • Any patients that have received any live vaccines within 30 days prior to enrollment

  • Tumors with primary localization to the brainstem or spinal cord

  • Severe, active co-morbidity, defined as follows:

    • Unstable angina and/or congestive heart failure requiring hospitalization.
    • Unstable cardiac arrhythmias, abnormalities, or transmural myocardial infarction within the last 6 months.
    • Acute bacterial or fungal infection requiring intravenous treatment at study treatment.
    • Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at study treatment
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
    • Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
    • Patients with autoimmune disease requiring medical management with immunosuppressants.
    • Major medical illnesses or psychiatric impairments that, in the investigator's opinion, will prevent administration or completion of protocol therapy.
    • Pregnancy or women of childbearing potential and men who are sexually active and who are unwilling or unable to use an acceptable method of contraception for the entire study period; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
  • Women of childbearing potential must not be pregnant or breast-feeding.

  • Participants who are receiving any other investigational agents or who have been treated on any other therapeutic clinical protocols within 30 days prior to projected first dose of study treatment.

  • Participants who are unwilling or unable to receive treatment and undergo follow-up evaluations

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Arm 1: pp65 RNA-LPs (DP1) before biopsy

Participants will receive pp65 RNA-LPs (DP1) starting before tumor biopsy/resection. All patients will receive three pp65 RNA-LP vaccines (DP1) before receiving full dose monthly RNA-LPs (RNA loaded lipid particles, RNA-LPs, DP2).

pp65 RNA loaded lipid particles or pp65 RNA-LPs administered intravenously

personalized tumor mRNA, pp65 fl LAMP mRNA and DOTAP liposomes or RNA loaded lipid particles, RNA-LPs administered intravenously

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of vaccines meeting release criteria in the DLT window during the first three vaccines
時間枠:from the date of surgery until administration of third vaccine, up to 20 weeks

Manufacturing feasibility will be determined based on the percentage of vaccines that are successfully manufactured in the DLT window during the first three vaccines. If two-thirds of vaccines are successfully manufactured with Qa/Qc clearance, the investigators will conclude that RNA-LPs can be successfully manufactured.

from the date of surgery until administration of third vaccine, up to 20 weeks
Incidence of investigational treatment related toxicities
時間枠:from first vaccine to 30 days after last dose of vaccine administered, up to 17 months

AEs and SAEs must be reported begins at time of first investigational product is received and ends 30 days after last investigational product is given.

from first vaccine to 30 days after last dose of vaccine administered, up to 17 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Ashley Ghiaseddin, MD、University of Florida

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年12月2日

一次修了 (推定)

2026年12月1日

研究の完了 (推定)

2027年12月1日

試験登録日

最初に提出

2024年4月24日

QC基準を満たした最初の提出物

2024年4月26日

最初の投稿 (実際)

2024年4月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年10月1日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 202301957
  • OCR44973 (その他の識別子:University of Florida)
  • R37CA251978 (米国 NIH グラント/契約)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。